Navigation Links
Neurologix Presents New Confirmatory Results for Phase 2 Study of NLX-P101 in Parkinson's Disease to Recombinant DNA Advisory Committee
Date:6/8/2011

the age of 50. According to the National Parkinson Foundation, 1 million Americans currently have PD, and an estimated 50,000 to 60,000 new cases are diagnosed each year in the United States. Standard therapy for PD often involves use of levodopa, a drug which stimulates production of dopamine. Unfortunately, many patients develop complications from this and other medications, or they can fail to be effective.  An alternative treatment is electrical deep brain stimulation, which requires the implantation of permanent medical devices in the brain.

About Neurologix

Neurologix, Inc. (OTCBB:NRGX) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of life-altering gene transfer therapies for serious disorders of the brain and central nervous system. Neurologix's therapeutic approach is built upon the groundbreaking research of its scientific founders and advisors, whose accomplishments have formed the foundation of gene therapy for neurological illnesses. The Company's current programs address such conditions as Parkinson's disease, epilepsy, depression and Huntington's disease, all of which are large markets not adequately served by current therapeutic options. For more information, please visit the Neurologix website at http://www.neurologix.net.

Cautionary Statement Regarding Forward-Looking Statements

This news release includes certain statements of the Company that may constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and which are made pursuant to the Private Securities Litigation Reform Act of 1995. These forward-looking statements and other information relating to the Company are based upon the beliefs of management and assumptions made by and information currently avai
'/>"/>

SOURCE Neurologix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. New Details Presented at the World Parkinson Congress on Neurologixs Successful Phase 2 Trial of Gene Therapy for Parkinsons Disease
2. Research Published in Science Translational Medicine Underscores Value of Depression Gene Therapy License Held by Neurologix
3. Neurologix Reports Third Quarter 2010 Financial Results
4. Neurologix Completes Additional $7 Million Financing
5. Neurologix Announces First Quarter 2011 Financial Results
6. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
7. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
8. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
9. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
10. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)...  Reportlinker.com announces that a new market research report ... and Taiwanese Markets for Minimally Invasive Spinal Devices ... The market for MIS spinal devices in the ... at a fast pace, albeit at different rates in ... China , where MIS spinal fusion ...
(Date:9/2/2014)... , Sept. 2, 2014 The Pharmaceutical Care ... benefit managers (PBMs), today filed a lawsuit in ... new Iowa law that restricts ... for the state,s employers and consumers.  ... by severely restricting the use of Maximum Allowable Cost ...
(Date:9/2/2014)... 2, 2014  XBiotech announced today interim results ... in the US for its anti-cancer agent Xilonix™. ... therapy, is being evaluated in advanced colorectal cancer ... The primary endpoint of the study is overall ... a control population provided only palliative therapy for ...
Breaking Medicine Technology:Chinese and Taiwanese Markets for Minimally Invasive Spinal Devices 2Chinese and Taiwanese Markets for Minimally Invasive Spinal Devices 3Chinese and Taiwanese Markets for Minimally Invasive Spinal Devices 4Chinese and Taiwanese Markets for Minimally Invasive Spinal Devices 5Chinese and Taiwanese Markets for Minimally Invasive Spinal Devices 6Chinese and Taiwanese Markets for Minimally Invasive Spinal Devices 7Chinese and Taiwanese Markets for Minimally Invasive Spinal Devices 8Chinese and Taiwanese Markets for Minimally Invasive Spinal Devices 9Lawsuit Challenges Iowa Health Mandate that Forces Employers to Pay More for Prescription Drugs 2XBiotech Halts Study, Reports Positive Phase III Results with Antibody Therapy for Cancer 2
... SEOUL, South Korea, Feb. 16, 2012   ,The ... the largest health care provider festival, is ... This Exhibition, for enhancing a national ... of hospital-related industry, is hosted by Korea ...
... Therapeutics, Inc. (NASDAQ: HALO ) today announced the ... its common stock, including 1,020,000 shares sold pursuant to the ... underwriter. All of the shares were offered by Halozyme at ... proceeds to Halozyme from this offering were approximately $81.8 million, ...
Cached Medicine Technology:To Take a Glance Cutting Edge Medicine Equipment! 'The 28th International Medical & Hospital Equipment Show' 2To Take a Glance Cutting Edge Medicine Equipment! 'The 28th International Medical & Hospital Equipment Show' 3Halozyme Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Stock 2Halozyme Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Stock 3
(Date:9/3/2014)... 03, 2014 "What can you say about ... "Margaret and Hillary," Book Eight in the Margaret of ... published by Wyston Books, Inc . These novels narrate ... in the richest town in America. , In this thriller, ... helps to investigate a student’s murder plot. Her fears increase ...
(Date:9/2/2014)... Autumn is well under way and famous review ... with worldwide people. Recently, it has made a ... http://secure.hostgator.com/~affiliat/cgi-bin/affiliates/clickthru.cgi?id=seohosts ), Arvixe, and Bluehost are the best ... 2002 HostGator has been known as a top ... reliability remains with it today. It is offering ...
(Date:9/2/2014)... today,s concentrated pot might be risky business for ... University. The study is the first to demonstrate ... THC. , Psychology professor Rebecca Craft showed ... are at least 30 percent more sensitive than ... active ingredient in cannabis. Females also develop tolerance ...
(Date:9/2/2014)... 2014 http://topcreatinemonohydrate.com/ , a ... obtain the latest information about muscle and fitness ... focuses mainly on testosterone and creatine ... their workout capacity and improve their athletic performance. ... Creatine Monohydrate, Muscle Advance Creatine is one of ...
(Date:9/2/2014)... Illinois (PRWEB) September 02, 2014 ... Chief Executive Officer and Chief Information Officer Strategy ... Carlton Chicago. , Becker's Hospital Review Chief Executive ... together hospital and health system Chief Executive Officers, ... hospital and health system executives through high-quality ...
Breaking Medicine News(10 mins):Health News:Town Locked Down After Bombing and Murders in "Margaret and Hillary" - New Book Eight in the Margaret of Greenwich(R) Young Adult Series by R. L. Rhyse 2Health News:Top10BestSEOHosting.com Celebrates The Coming Of Autumn And Release Reseller Hosting Suppliers Of 2014 2Health News:Estrogen increases cannabis sensitivity 2Health News:Estrogen increases cannabis sensitivity 3Health News:Creatine Monohydrate Reviews Site TopCreatineMonohydrate.com Announces its Launch 2Health News:Becker's Healthcare Announces Hospital CEO and CIO Strategy Roundtables 2Health News:Becker's Healthcare Announces Hospital CEO and CIO Strategy Roundtables 3Health News:Becker's Healthcare Announces Hospital CEO and CIO Strategy Roundtables 4
... Inc. (Nasdaq: MEDQ ), the largest Medical Transcription ... the positive resolution of several material legal matters , ... Investigation , , As ... documents from the United States Department of Justice ("DOJ") on ...
... College of Surgeons (ACS) today recognized the Institute of Medicine ... was released on December 2, 2008, by the IOM Committee ... to Improve Patient Safety. , ... conclusion that further reductions in the mandated 80-hour work week ...
... YORK, Dec. 3, 2008 Forest Laboratories, Inc. (NYSE: ... of an unsolicited mini-tender offer by TRC Capital Corporation (TRC) ... has received a copy of the tender offer to purchase ... stock, which represents less than 1 per cent of its ...
... MAP,Pharmaceuticals, Inc. (Nasdaq: MAPP ) today announced ... "Adapting Specialty Pharma Strategy,To Market Conditions" at the 2008 ... at 10:00 am (ET) in New York City. , ... of the panel discussion will be available on the ...
... outperform animal and human derived serum in CHO cell culture. ... ... Cellastim has proven to be a robust replacement for serum derived ... and productivity of CHO cell lines across a variety of chemically ...
... N.J., Dec. 3 As previously announced, HLTH Corporation (Nasdaq: ... (Nasdaq: WBMD ), will be holding their Annual Meetings ... 10, 2008. , , ... the Internet. To listen to the audio webcast of the meetings, ...
Cached Medicine News:Health News:MedQuist Announces Resolution of the DOJ Investigation and Dismissal of Shareholder Lawsuits 2Health News:MedQuist Announces Resolution of the DOJ Investigation and Dismissal of Shareholder Lawsuits 3Health News:MedQuist Announces Resolution of the DOJ Investigation and Dismissal of Shareholder Lawsuits 4Health News:MedQuist Announces Resolution of the DOJ Investigation and Dismissal of Shareholder Lawsuits 5Health News:MedQuist Announces Resolution of the DOJ Investigation and Dismissal of Shareholder Lawsuits 6Health News:American College of Surgeons Comments on Institute of Medicine Report on Resident Duty Hours 2Health News:Forest Laboratories Responds To Unsolicited Mini-Tender Offer 2Health News:Forest Laboratories Responds To Unsolicited Mini-Tender Offer 3Health News:InVitria's Cellastim Delivers Superior Results in CHO Cell Culture 2Health News:HLTH Corporation and WebMD to Webcast Annual Meetings of Stockholders 2
...
... The mecA ASR contains primers and a FAM-labeled ... bp region of the mecA gene. In addition, ... and DNA for an internal control sequence. This ... and Texas Red reporter dyes such as the ...
... features the ability to use a separate, ... a pre-loaded nitinol filter with a dual-ended ... fully rapid exchange system, the SpideRX Device ... applications:, Carotid Indication - ,The SpideRX Embolic ...
Pefakit PiCT DxS Diluent for Determination of Total Heparin...
Medicine Products: